Good to see: high throughput, inexpensive DNA sequencing is being featured on NPR this week in a series entitled the $1,000 Genome. Many of the technologies for this revolution in sequencing, of course, relate closing to or directly are nanotechnology (e.g., nanopore, microfluidic, and/or lab-on-a-chip technologies). Personalized medicine depends on it. More generally, the interface between biology and electronics is one of the most compelling arguments for further development and commercialization of nanotechnology and, more particularly, bio nanotechnology. Another leading example is allowing partially blind or blind persons to see better with artificial retinas.
A brief check of the nanotechnology class 977 patent literature shows IBM has activity in this area. See, for example, their recent US patent publications 2012/0199483 (published August 9, 2012); 2012/0193237 (published August 2, 2012); 2011/0308949 (December 22, 2011); and 2011/0279125 (November 17, 2011).
Hopefully, angel and venture capital investment will also flow to these exciting areas. This appears to be turning out to be one of many virtually secret “killer apps” for nanotech. For example, the NPR series does not delve too much into how the sequencing is done (per the series, sequencing done in a ”black box”). Hopefully, despite the secrecy, the federal and state governments, including those who fund and run the NNI, are watching.